18. Enterprise-wide Disclosures

Geographic Area Information

Revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the licensee or grantor.

Geographic Area	Revenues for the Year ending December 31,
	2011		2010		2009

Domestic	$	2,980,413	$	3,283,493	$	1,549,066
Asia		1,374,349		396,807		376,102
Total revenues	$	4,354,762	$	3,680,300	$	1,925,168

Major Sources of Revenues

BioTime has four major customers and three major grants comprising significant amounts of total revenues.

All of BioTime's royalty revenues were generated through sales of Hextend® by Hospira in the U.S. and by CJ in the Republic of Korea. BioTime also earned license fees from CJ and Summit.

BioTime was awarded a $4,721,706 grant for a stem cell research project related to its ACTCellerate™ technology by CIRM in April 2009. The CIRM grant covers the period of September 1, 2009 through August 31, 2012, and as of December 31, 2011 and 2010, BioTime had received payments from CIRM totaling $1,570,663 and $1,575,523, respectively. BioTime recognized $1,570,663 and $1,577,142 as revenues as of December 31, 2011 and 2010, respectively.

During 2011, BioTime also received and recognized as revenues $27,917 of a $335,900 grant awarded by the NIH. The grant started on September 30, 2011 and ends on September 29, 2012.

During 2011, grant income also included awards from other sources in the amount of $94,933 was recognized through OncoCyte and OrthoCyte.

During 2011, grant income from the Office of the Chief Scientist of the Ministry of Industry, Trade, and Labor of Israel (“OCS”) in the amount of $1,073,668 was also recognized through our ownership interest in Cell Cure Neurosciences. No grant income from OCS was recognized in 2010.

During 2010, BioTime received $476,724 of a $733,438 grant awarded under the U.S. Government's QTDP. The entire amount of the award is recognized as revenues as of December 31, 2010. BioTime received the remaining award amount of $256,714 in February 2011.

The following table shows the relative portions of BioTime's Hextend® and PentaLyte® royalty and license fee revenues paid by Hospira, CJ, Summit and the Betalogics division of Johnson & Johnson that were recognized during the years ended December 31, 2011, 2010, and 2009, and the OCS, CIRM and QTDP grant payments recognized during the same periods:

Sources of Revenues	% of Total Revenues for Year ended December 31,
	2011		2010		2009
Hospira		14.5%		22.8%		51.8%
CJ		3.6%		7.0%		12.0%
Summit		3.3%		3.9%		7.6%
CIRM		36.1%		42.8%		27.7%
QTDP		-		19.9%		-
OCS		23.4%		-		-
Betalogics		9.0%		-		-
Others		10.1%		3.6%		0.9%